GlassScriptPhysician profile
Jorge E Nunez
NPI 1629697065
$2,441.21
in general payments reported to CMS, 2019-2025
26 companies · $980 in 2025
The $980 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $519 · 2024: $942 · 2025: $980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,441.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $249.79 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $225.94 | 2024-2025 | Fasenra, Farxiga, Airsupra |
| Mallinckrodt Hospital Products INC. | $213.75 | 2023-2024 | Acthar |
| Ani Pharmaceuticals, INC. | $185.41 | 2024-2025 | Purified Cortrophin Gel |
| Angiodynamics, INC. | $159.61 | 2023 | Nanoknife |
| Novo Nordisk INC | $153.72 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Verona Pharma, INC. | $151.00 | 2025 | Ohtuvayre |
| Exact Sciences Corporation | $125.33 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $125.02 | 2024-2025 | |
| Viatris Specialty LLC | $104.33 | 2025 | Yupelri |
| Viiv Healthcare Company | $103.65 | 2023 | Dovato |
| Lilly USA, LLC | $91.41 | 2024-2025 | Zepbound, Mounjaro |
| Genzyme Corporation | $86.73 | 2023-2025 | |
| Boston Scientific Corporation | $67.91 | 2024-2025 | Accolade Sr, Watchman Flx |
| Idorsia Pharmaceuticals US INC | $65.84 | 2023-2024 | Quviviq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $49.74 | 2024 | |
| Grifols USA, LLC | $43.64 | 2025 | Prolastin-C Liquid |
| Astellas Pharma US INC | $42.51 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $37.36 | 2024 | Winrevair, Gardasil 9, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.84 | 2024 | Xifaxan |
| Corcept Therapeutics | $27.22 | 2025 | Korlym |
| Sumitomo Pharma America, INC. | $23.80 | 2024 | Gemtesa |
| Janssen Pharmaceuticals, INC | $20.87 | 2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.06 | 2024 | Ofev |
| Ardelyx, INC. | $18.80 | 2024 | Ibsrela |
| Amgen INC. | $15.93 | 2024 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Nunez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.